ClearPoint Neuro, Inc. (NASDAQ: CLPT) is a Healthcare company in the Medical - Devices industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | -1.01 | Insider Own | 5.49% | Shs Outstand | 29.99M | Perf Week | 5.81% |
| Market Cap | 448.04M | Forward P/E | - | EPS next Y | -0.94 | Insider Trans | -7.80% | Shs Float | 26.27M | Perf Month | -20.19% |
| Enterprise Value | 476.04M | PEG | 0.56 | EPS next Q | - | Inst Own | - | Short Float | 14.07% | Perf Quarter | 33.63% |
| Income | -29.48M | P/S | 11.03 | EPS this Y | -10.23% | Inst Trans | - | Short Ratio | 5.29 | Perf Half Y | 11.33% |
| Sales | 40.61M | P/B | 23.43 | EPS next Y | 15.57% | ROA | -31.11% | Short Interest | 3.70M | Perf YTD | 9.21% |
| Book/sh | - | P/C | - | EPS next 5Y | - | ROE | -140.96% | 52W High | 30.99 -50.37% | Perf Year | 40.15% |
| Cash/sh | - | P/FCF | - | EPS past 3/5Y | - | ROIC | -31.46% | 52W Low | 8.51 80.65% | Perf 3Y | 128.44% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | 20.78% 23.27% | Gross Margin | 61.82% | Volatility | 5.29% 5.13% | Perf 5Y | -25.86% |
| Dividend TTM | - | EV/Sales | 11.72 | EPS Y/Y TTM | -44.29% | Oper. Margin | -65.20% | ATR (14) | 0.93 | Perf 10Y | 69.77% |
| Dividend Ex-Date | - | Quick Ratio | 4.88 | Sales Y/Y TTM | 29.03% | Profit Margin | -71.57% | RSI (14) | 46.58 | Recom | 2.00 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.79 | EPS Q/Q | -45.45% | SMA20 | -4.66% | Beta | 1.18 | Target Price | 16.00 |
| Payout | 0.00% | Debt/Eq | 3.38 | Sales Q/Q | 50.00% | SMA50 | -1.14% | Rel Volume | 0.84 | Prev Close | 14.94 |
| Employees | 172 | LT Debt/Eq | 2.04 | Earnings | Aug 03 | SMA200 | 5.04% | Avg Volume | 720.53K | Price | 15.38 |
| IPO Date | May 22, 2012 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -17.07% 1.35% | Net Debt/EBITDA | -1.18 | Volume | 605,339 | Change | 2.95% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jun-09-26 | Reiterated | Stifel Nicolaus | $9.00 → $16 | |
| Jan-21-25 | Reiterated | Lake Street | Buy | $30 |
| Aug-27-24 | Reiterated | Loop Capital Markets | $15 | |
| Mar-13-24 | Reiterated | Stifel Nicolaus | $9.00 |
ClearPoint Neuro, Inc. is a medical technology firm primarily operating within the United States. The company specializes in developing and commercializing sophisticated systems that facilitate minimally invasive brain surgeries, guided by real-time magnetic resonance imaging (MRI) during the procedure. Among its core offerings is the ClearPoint system, designed for the precise placement of deep brain stimulation electrodes, biopsy needles, and for the controlled infusion of medications and laser catheters directly into the brain. It also provides the ClearPoint Neuro Navigation System, which is specifically engineered for MRI suite environments. ClearPoint Neuro maintains strategic partnerships and licensing agreements with prominent institutions and companies, including Boston Scientific Corporation, The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Neurotech, and the University of California, San Francisco. Initially established in 1998 and headquartered in Solana Beach, California, the company operated as MRI Interventions, Inc. before rebranding to ClearPoint Neuro, Inc. in February 2020.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 40 | 37 | 31 | 24 | 21 | 16 | 13 | 11 | 7 | |
| Cost of Goods Sold Incl. D&A | 16 | 14 | 12 | 10 | 7 | 5 | 4 | 4 | 2 | |
| Gross Profit | 26 | 23 | 19 | 14 | 14 | 11 | 9 | 7 | 5 | |
| Selling, General and Administrative Excl. Other | 37 | 33 | 26 | 24 | 19 | 15 | 11 | 9 | 8 | |
| Research and Development | 15 | 14 | 12 | 12 | 11 | 9 | 5 | 3 | 2 | |
| Other Operating Expense | -1 | 0 | 1 | 0 | 0 | 0 | -1 | 0 | 0 | |
| Operating Income | -26 | -24 | -20 | -22 | -16 | -13 | -6 | -5 | -5 | |
| Interest Expense | 3 | 2 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | |
| Net Income Before Taxes | -30 | -25 | -19 | -22 | -16 | -14 | -7 | -6 | -6 | |
| Income Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Consolidated Net Income | -30 | -26 | -19 | -22 | -16 | -14 | -7 | -6 | -6 | |
| Net Income From Continuing Operations | -30 | -26 | -19 | -22 | -16 | -14 | -7 | -6 | -6 | |
| Net Income | -30 | -26 | -19 | -22 | -16 | -14 | -7 | -6 | -6 | |
| EPS (Recurring) | -1.01 | -0.90 | -0.70 | -0.90 | -0.68 | -0.69 | -0.43 | -0.49 | -0.56 | |
| EPS (Basic, Before Extraordinaries) | -1.01 | -0.90 | -0.70 | -0.90 | -0.68 | -0.69 | -0.43 | -0.49 | -0.56 | |
| EPS (Diluted) | -1.01 | -0.90 | -0.70 | -0.90 | -0.68 | -0.69 | -0.43 | -0.49 | -0.56 | |
| EBITDA | -23 | -21 | -17 | -21 | -16 | -13 | -5 | -4 | -5 | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 11.54 | 10.35 | 13.40 | 7.07 | 9.68 | 14.73 | 19.56 | 5.67 | 2.47 | |
| Gross Margin | 65.00 | 62.16 | 61.29 | 58.33 | 66.67 | 68.75 | 69.23 | 63.64 | 71.43 | |
| Operating Margin | -65.00 | -64.86 | -64.52 | -91.67 | -76.19 | -81.25 | -46.15 | -45.45 | -71.43 | |
| Net Margin | -75.00 | -70.27 | -61.29 | -91.67 | -76.19 | -87.50 | -53.85 | -54.55 | -85.71 | |
| Shares Outstanding | 30 | 28 | 27 | 25 | 24 | 21 | 16 | 13 | 11 | |
| Market Capitalization | 461 | 383 | 415 | 170 | 203 | 236 | 254 | 62 | 17 | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| BURNETT JOSEPH | CEO and President | Jun 29 '26 | Option Exercise | 2.50 | 20,000 | 50,000 | 136,842 | Jul 01 |
| BURNETT JOSEPH | CEO and President | Jun 29 '26 | Sale | 19.38 | 20,000 | 387,600 | 116,842 | Jul 01 |
| BURNETT JOSEPH | CEO and President | Jun 17 '26 | Sale | 17.79 | 61,843 | 1,100,463 | 116,842 | Jun 22 |
| BURNETT JOSEPH | CEO and President | Jun 17 '26 | Option Exercise | 2.50 | 60,000 | 150,000 | 176,842 | Jun 22 |
| Richards Timothy T. | Director | Jun 04 '26 | Option Exercise | 10.00 | 500 | 5,000 | 87,698 | Jun 08 |
| Richards Timothy T. | Director | Jun 01 '26 | Sale | 12.17 | 5,415 | 65,901 | 87,198 | Jun 02 |
| Klein Matthew B. | Director | May 21 '26 | Sale | 11.59 | 16,000 | 185,440 | 46,935 | May 26 |
| FALLON LYNNETTE C | Director | May 20 '26 | Sale | 11.14 | 5,091 | 56,714 | 48,227 | May 21 |
| JOHNSON B KRISTINE | Director | May 19 '26 | Option Exercise | 0.00 | 12,417 | 0 | 71,116 | May 21 |
| Klein Matthew B. | Director | May 19 '26 | Option Exercise | 0.00 | 12,417 | 0 | 62,935 | May 21 |
| FALLON LYNNETTE C | Director | May 19 '26 | Option Exercise | 0.00 | 12,417 | 0 | 53,318 | May 21 |
| FLETCHER R JOHN | Director | May 19 '26 | Option Exercise | 0.00 | 12,417 | 0 | 130,349 | May 21 |
| Richards Timothy T. | Director | May 19 '26 | Option Exercise | 0.00 | 12,417 | 0 | 92,613 | May 21 |
| Girin Pascal E R | Director | May 19 '26 | Option Exercise | 0.00 | 12,417 | 0 | 110,623 | May 21 |
| LIAU LINDA M. | Director | May 19 '26 | Option Exercise | 0.00 | 12,417 | 0 | 64,801 | May 21 |